NO20091490L - Fremgangsmate for a optimalisere behandlingen av filadelfia-positiv leukemi med Abl tyrosinkinaseinhibitorer - Google Patents
Fremgangsmate for a optimalisere behandlingen av filadelfia-positiv leukemi med Abl tyrosinkinaseinhibitorerInfo
- Publication number
- NO20091490L NO20091490L NO20091490A NO20091490A NO20091490L NO 20091490 L NO20091490 L NO 20091490L NO 20091490 A NO20091490 A NO 20091490A NO 20091490 A NO20091490 A NO 20091490A NO 20091490 L NO20091490 L NO 20091490L
- Authority
- NO
- Norway
- Prior art keywords
- leukemia
- tyrosine kinase
- abl tyrosine
- cmin
- bcr
- Prior art date
Links
- 208000032839 leukemia Diseases 0.000 title abstract 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 229940124290 BCR-ABL tyrosine kinase inhibitor Drugs 0.000 abstract 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 abstract 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract 1
- 102000004441 bcr-abl Fusion Proteins Human genes 0.000 abstract 1
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 229960002411 imatinib Drugs 0.000 abstract 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 210000004214 philadelphia chromosome Anatomy 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Ecology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Foreliggende oppfinnelse tilveiebringer en fremgangsmåte for behandling av Philadelphia positiv (Ph+) leukemi, slik som Philadelphia kromosom positiv akutt lymfoblastisk leukemi (Ph + ALL) eller kronisk myeloid leukemi (CML) hos en menneskepasient populasjon som innbefatter trinnet med å (a) administrere en forhåndsbestemt fiksert mengde av en Bcr-Abl tyrosin kinase inhibitor, slik som imatinib, eller et farmasøytisk akseptabelt salt derav til menneskepasienter som lider av Ph+ leukemi (b) samle opp minst en blodprøve fra nevnte pasienter (c) bestemme plasma "trough" nivået (Cmin) av Ber-Abl tyrosin kinase inhibitoren eller en metabolitt derav så vel som MMR gradene, (d) bestemme et diskriminerende potensial av "trough" plasmakonsentrasjoner for MMR og identifisere en Cmin terskel for optimal sensitivitet og spesifisitet og (e) justere dosen av inhibitoren av Ber-Abl tyrosin kinasen eller et farmasøytisk akseptabelt salt derav anvendt på de individuelle pasientene fra nevnte pasientpopulasjon og, eventuelt fremtidige pasienter som lider av en Ph+ leukemi på en måte slik at en Cmin oppnås i hver enkelt pasient lik med eller høyere enn Cmin terskelen oppnådd under trinn (d).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82662206P | 2006-09-22 | 2006-09-22 | |
| US82827806P | 2006-10-05 | 2006-10-05 | |
| PCT/US2007/078978 WO2008036792A2 (en) | 2006-09-22 | 2007-09-20 | Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20091490L true NO20091490L (no) | 2009-06-15 |
Family
ID=39092883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20091490A NO20091490L (no) | 2006-09-22 | 2009-04-16 | Fremgangsmate for a optimalisere behandlingen av filadelfia-positiv leukemi med Abl tyrosinkinaseinhibitorer |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20090281113A1 (no) |
| EP (2) | EP2251042A3 (no) |
| JP (1) | JP5735742B2 (no) |
| KR (1) | KR20090065512A (no) |
| AT (1) | ATE495761T1 (no) |
| AU (1) | AU2007299764B2 (no) |
| BR (1) | BRPI0717099A2 (no) |
| CA (1) | CA2662977A1 (no) |
| CL (1) | CL2007002725A1 (no) |
| CY (1) | CY1111356T1 (no) |
| DE (1) | DE602007012122D1 (no) |
| DK (1) | DK2068938T3 (no) |
| HR (1) | HRP20110250T1 (no) |
| IL (1) | IL197296A (no) |
| MA (1) | MA30786B1 (no) |
| MX (1) | MX2009003082A (no) |
| NO (1) | NO20091490L (no) |
| NZ (1) | NZ575113A (no) |
| PL (1) | PL2068938T3 (no) |
| PT (1) | PT2068938E (no) |
| TN (1) | TN2009000094A1 (no) |
| TW (1) | TWI398251B (no) |
| WO (1) | WO2008036792A2 (no) |
| ZA (1) | ZA200901220B (no) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101951910B (zh) | 2008-01-23 | 2013-07-17 | 诺瓦提斯公司 | 优化用伊马替尼治疗酪氨酸激酶受体kit介导的增殖性疾病的制药用途 |
| JP2012510470A (ja) * | 2008-12-01 | 2012-05-10 | ノバルティス アーゲー | メシル酸イマチニブを用いたフィラデルフィア陽性白血病の処置を最適化する方法 |
| US20110046919A1 (en) * | 2009-03-02 | 2011-02-24 | Juliesta Elaine Sylvester | Method for accurate measurement of enzyme activities |
| FR2943418A1 (fr) * | 2009-03-17 | 2010-09-24 | Centre Nat Rech Scient | Procedes de mesure de la quantite intracellulaire de molecules d'interet intrinsequement fluorescentes par cytometrie en flux et leurs applications |
| EP3072964A1 (en) * | 2013-11-22 | 2016-09-28 | National Center For Child Health And Development | Novel chimera gene atf7ip-pdgfrb for acute lymphoblastic leukemia |
| CN108271374B (zh) | 2015-07-07 | 2021-09-21 | 科德克希思公司 | 具有改进的活性的新颖p450-bm3变体 |
| IT201900008808A1 (it) | 2019-06-13 | 2020-12-13 | Univ Ca Foscari | Metodo per la determinazione della concentrazione di 4-[(4-metil-1-piperazinil)metil]-n-(4-metil-3-{[4-(3-piridinil)-2-pirimidinil]-ammino}fenil)benzammide(imatinib) in campioni di plasma |
| CN114994213A (zh) * | 2022-06-28 | 2022-09-02 | 北京赛诺浦生物技术有限公司 | 一种测定人血浆中抗肿瘤药物酪氨酸激酶抑制血药浓度的试剂盒及测定方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| EP2308833A3 (en) | 1999-04-15 | 2011-09-28 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| GB0202873D0 (en) | 2002-02-07 | 2002-03-27 | Novartis Ag | Organic compounds |
| JP2005522221A (ja) * | 2002-04-17 | 2005-07-28 | ノバルティス アクチエンゲゼルシャフト | チロシンキナーゼ阻害剤に対する患者応答性の予測方法 |
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| GB0222514D0 (en) | 2002-09-27 | 2002-11-06 | Novartis Ag | Organic compounds |
| RU2401265C2 (ru) | 2004-06-10 | 2010-10-10 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеинкиназы |
| GB0421525D0 (en) | 2004-09-28 | 2004-10-27 | Novartis Ag | Inhibitors of protein kineses |
| MY148074A (en) | 2005-05-10 | 2013-02-28 | Novartis Ag | Pharmaceutical compositions comprising imatinib and a release retardant |
-
2007
- 2007-09-20 AU AU2007299764A patent/AU2007299764B2/en not_active Ceased
- 2007-09-20 BR BRPI0717099-8A patent/BRPI0717099A2/pt not_active IP Right Cessation
- 2007-09-20 CA CA002662977A patent/CA2662977A1/en not_active Abandoned
- 2007-09-20 WO PCT/US2007/078978 patent/WO2008036792A2/en not_active Ceased
- 2007-09-20 KR KR1020097005757A patent/KR20090065512A/ko not_active Ceased
- 2007-09-20 EP EP10171365A patent/EP2251042A3/en not_active Withdrawn
- 2007-09-20 MX MX2009003082A patent/MX2009003082A/es active IP Right Grant
- 2007-09-20 NZ NZ575113A patent/NZ575113A/en not_active IP Right Cessation
- 2007-09-20 HR HR20110250T patent/HRP20110250T1/hr unknown
- 2007-09-20 US US12/442,126 patent/US20090281113A1/en not_active Abandoned
- 2007-09-20 DE DE602007012122T patent/DE602007012122D1/de active Active
- 2007-09-20 PT PT07842842T patent/PT2068938E/pt unknown
- 2007-09-20 DK DK07842842.2T patent/DK2068938T3/da active
- 2007-09-20 AT AT07842842T patent/ATE495761T1/de active
- 2007-09-20 PL PL07842842T patent/PL2068938T3/pl unknown
- 2007-09-20 JP JP2009529384A patent/JP5735742B2/ja not_active Expired - Fee Related
- 2007-09-20 EP EP07842842A patent/EP2068938B1/en active Active
- 2007-09-21 TW TW096135633A patent/TWI398251B/zh not_active IP Right Cessation
- 2007-09-21 CL CL200702725A patent/CL2007002725A1/es unknown
-
2009
- 2009-02-20 ZA ZA2009/01220A patent/ZA200901220B/en unknown
- 2009-02-26 IL IL197296A patent/IL197296A/en not_active IP Right Cessation
- 2009-03-19 TN TN2009000094A patent/TN2009000094A1/fr unknown
- 2009-04-10 MA MA31775A patent/MA30786B1/fr unknown
- 2009-04-16 NO NO20091490A patent/NO20091490L/no not_active Application Discontinuation
-
2011
- 2011-03-23 CY CY20111100319T patent/CY1111356T1/el unknown
-
2016
- 2016-09-22 US US15/272,576 patent/US20170007605A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20091490L (no) | Fremgangsmate for a optimalisere behandlingen av filadelfia-positiv leukemi med Abl tyrosinkinaseinhibitorer | |
| EA201690111A1 (ru) | Имидазопиразиновые ингибиторы тирозинкиназы syk | |
| HUP0302332A2 (hu) | Génkimutatási eljárás ErbB-antagonistával végzett rákterápiára adott hatékony reakció valószínûségének növelésére | |
| KR20050037510A (ko) | 키나제 억제제를 사용하는 암 치료 방법 | |
| Savastano et al. | Antioxidant therapy in idiopathic tinnitus: preliminary outcomes | |
| KR102425655B1 (ko) | 수면 개선 방법 | |
| EP1720574A4 (en) | METHOD FOR THE TREATMENT OF ABNORMAL CELL GROWTH WITH C-MET AND TOR HEMMERN | |
| EA201071422A1 (ru) | Способы лечения заболеваний, связанных с мейотическим кинезином | |
| WO2010066891A3 (en) | Method for predicting the response to treatment by tyrosine kinase inhibitors targeting the bcr-abl fusion protein in chronic myeloid leukaemia patients | |
| BRPI0518795A2 (pt) | mÉtodos para determinar a eficÁcia de um tratamento terapÊutico anti-inflamatàrio de um indivÍduo e para selecionar um indivÍduo que sofre de uma certa doenÇa inflamatària para receber tratamento terapÊutico anti-inflamatàrio | |
| RU2010101634A (ru) | Способ оптимизации лечения хронического миелолейкоза с помощью ингибиторов трирозинкиназы abi | |
| DK2196199T3 (da) | Behandling af fantomfænomener | |
| RU2020134183A (ru) | Способ ингибирования пути egf/egfr в комбинации с ингибиторами тирозинкиназы | |
| EA201300410A1 (ru) | Стратификация страдающих раком пациентов по чувствительности к терапии с использованием ингибиторов ptk2 | |
| Abbasian et al. | Sirtuin1 and Chronic Myeloid Leukemia: a Comprehensive Glance at Drug Resistance. | |
| TW200507828A (en) | Method for treatment of chemotherapy-induced diarrhea | |
| RU2483732C2 (ru) | СПОСОБ ОПТИМИЗАЦИИ ЛЕЧЕНИЯ ЛЕЙКОЗА, ПОЛОЖИТЕЛЬНОГО ПО ФИЛАДЕЛЬФИЙСКОЙ ХРОМОСОМЕ, ИНГИБИТОРАМИ Ab1-ТИРОЗИНКИНАЗЫ | |
| Rodriguez et al. | AB0165 THE ROLE OF CXCL4, CXCL8 AND GDF-15 IN SYSTEMIC SCLEROSIS | |
| Radich | The (near) miracle of therapy in chronic myeloid leukaemia. | |
| CN102526734A (zh) | 治疗年龄相关性听力损失的药物组合物及其应用 | |
| WO2010065433A1 (en) | Method of optimizing the treatment of philadelphia-positive leukemia with imatinib mesylate | |
| WO2001045690A3 (en) | Use of bvdu for inhibiting the growth of hyperproliferative cells | |
| ATE312612T1 (de) | Methode zur optimierung der verwendung von 6- mercaptopurin in der behandlung von immun- vermittelten gastrointestinalen störungen | |
| Snead et al. | New strategies for the first-line treatment of chronic myeloid leukemia: can resistance be avoided? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |